Project Grant R43CA310451
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $399K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Champaign, IL 61820, USA
Similar Awards
- The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...
- The National Cancer Institute awarded $1,057,841 to Pathware Inc. on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) as a Small Business Innovation Research Direct-to-Phase II grant (R44CA302204). Pathware is developing an automated imaging platform combining coded ptychography with artificial intelligence algorithms to evaluate the diagnostic adequacy of unstained lung biopsy samples at the point of care. The system provides rapid on-site evaluation...
- Federal Project Grant Award Summary Award Details: The National Cancer Institute (NCI) awarded O2M Technologies LLC a $1,164,814 Project Grant on September 19, 2025, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for research extending through August 31, 2027. The award supports the development of advanced imaging methods in pulse electron paramagnetic resonance (EPR) to enable precise partial oxygen pressure (pO2) measurements for cancer diagnosis and treatment...
- The National Cancer Institute awarded Ramona Optics Inc. $306,872 on September 9, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop a multi-camera array scanner (MCAS) that rapidly digitizes and automatically analyzes fine-needle aspiration (FNA) cytology smears in three dimensions. The MCAS system will provide real-time imaging to enable rapid on-site evaluation (ROSE) of FNA biopsy specimens during procedures such as bronchoscopies. Current limitations in ROSE...
- The National Cancer Institute awarded Northeastern University $1,144,692 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for precision cancer microsurgery using laser ablation-cooling with pulse bursts. The project develops a novel handheld microsurgical device that integrates video cellular-resolution microendoscopy with high-speed pulsed laser ablation to enable rapid visualization and eradication of microscopic tumor deposits at surgical margins...
- The National Cancer Institute awarded $400,000 to Zeest Bio Inc. on September 15, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a novel liver-specific positron emission tomography tracer for improved detection of metastatic tumors and assessment of liver function and biliary tract pathology. The recipient will complete preclinical testing and investigational new drug-enabling studies in preparation for first-in-human clinical trials. Current imaging...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $648,049 to the University of California Irvine on April 2, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop protoacoustic imaging technology for real-time localization of the Bragg peak during proton therapy. The project, led by Principal Investigator Shawn (Liangzhong) Xiang, addresses the challenge of accurately positioning...
- The National Science Foundation awarded Lightfinder Inc. $1,247,250 in a Cooperative Agreement on August 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop chip-scale optical coherence tomography (OCT) imaging technology for pathology applications. The Phase II Small Business Innovation Research project integrates photonic interferometry, beam steering, and detection into a single silicon chip using scalable CMOS-compatible manufacturing methods. The...
- This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $437,113 to Massachusetts Eye and Ear Infirmary on June 8, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop fluorescence lifetime imaging methods for quantifying in vivo PD-L1 target engagement in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitor monoclonal antibodies. The project addresses a...